Document is current
Any future updates will be listed below
-
Authors
Zhou, Yaxian
Li, Chunrong
Chen, Xuankun https://orcid.org/0000-0001-6006-7360
Zhao, Yuan
Liao, Yaxian
Huang, Penghsuan https://orcid.org/0000-0002-5058-5399
Wu, Wenxin
Nieto, Nicholas S.
Li, Lingjun https://orcid.org/0000-0003-0056-3869
Tang, Weiping https://orcid.org/0000-0002-0039-3196
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA284689, P30CA014520)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | Center for Scientific Review (S10RR029531, S10OD028473, S10OD025084, DK071801, R01 AG052324, R01AG078794)
U.S. Department of Health & Human Services | NIH | Center for Scientific Review
- License Information
-
More Information
Article History
Received: 15 December 2023
Accepted: 19 September 2024
First Online: 8 October 2024
Competing interests
: A patent (WO2023183381A3, Inventors: Weiping Tang, Yaxian Zhou, Chunrong Li, and Hao Wu) related to this manuscript has been filed by Wisconsin Alumni Research Foundation, which acts as the technology transfer entity for the University of Wisconsin-Madison. The patent has been published. The use of folate as the ligand of lysosome targeting receptor to develop FRTACs for degrading disease-associated proteins is covered in the patent application. W.T. is the co-founder and shareholder of Chimergen Therapeutics Inc. The remaining authors declare no competing interests.
